Product
TH1902
1 clinical trial
10 indications
Indication
Solid TumorIndication
Triple-Negative Breast CancerIndication
Hormone Receptor-positive Breast CancerIndication
Ovarian CancerIndication
Endometrial CancerIndication
MelanomaIndication
Thyroid CancerIndication
Small Cell Lung CancerIndication
Prostate CancerIndication
SORT1+ CancersClinical trial
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-01